Symptomatic treatment of Raynaud's phenomenon: reserpine, alpha-methyldopa, griseofulvin, guanethidine
Zicot, M.
Revue Medicale de Liege 35(19): 652-654
1980
ISSN/ISBN: 0370-629X PMID: 6161403 Document Number: 167492
Document emailed within 1 workday
Related Documents
Acevedo, A.; Arinoviche, R.; Palma, A.; Olea, E.; Guzmán, G.; Arriagada, M.; Grisanti, M.; Testar, R. 1982: Reserpine administration by retrograde intravenous route in patients with Raynaud's phenomenon Revista Medica de Chile 110(11): 1063-1065Rankin, G.O.; Watkins, B.E.; Sawutz, D.G. 1982: Chlorpromazine interactions with guanethidine and alpha-methyldopa: effects on arterial pressure control and heart rate in renovascular hypertensive rats Archives Internationales de Pharmacodynamie et de Therapie 260(1): 130-140
Dunn, M.I.; Freeman, J. 1975: Moderate hypertension: treatment with guanethidine and methyldopa Current Therapeutic Research 18(2): 285-294
Cuenca, R.; Fernández-Cortijo, J.; Lima, J.; Fonollosa, V.; Simeón, C.P.; Pico, M.; Soriano, B.; Vilardell, M. 1990: Platelet function study in primary Raynaud's phenomenon and Raynaud's phenomenon associated with scleroderma Medicina Clinica 95(20): 761-763
Pratesi, F.; Corsi, C.; Deidda, C.; Nuti, A. 1976: Raynaud's phenomenon and Raynaud's disease definition of Raynaud's phenomenon Schweizerische Rundschau für Medizin Praxis 65(44): 1368-1370
Tarpley, E.L. 1974: Controlled trial of guanethidine and methyldopa in moderate hypertension Current Therapeutic Research 16(11): 1187-1196
Bart, P.A.; Waeber, B. 2006: Understanding Raynaud's phenomenon: towards a better treatment Revue Medicale Suisse 2(48): 93-96
Thulesius, O. 1979: Psychiatric treatment of Raynaud's phenomenon Lakartidningen 76(47): 4234
Kállay, K.; Káldor, A.; Gachályi, B.; Sebestyén, K.; Földvári, A. 1974: The effect of guanethidine and reserpine in angiotensin sensitivity in man Orvosi Hetilap 115(49): 2917-2919
Tindall, J.P.; Whalen, R.E.; Burton, E.E. 1974: Medical uses of intra-arterial injections of reserpine. Treatment of Raynaud syndrome and of some vascular insufficiencies of the lower extremities Archives of Dermatology 110(2): 233-237
Delgado Daza, R.; Moga Donadeu, L.; Mañosa Bonamich, J.; Muncunill Gil, J.; Vidal Conde, V. 1991: Thoracic sympathectomy in the surgical treatment of Raynaud's phenomenon Angiologia 43(5): 180-182
Buryĭ, V.T.; Buryĭ, V.V. 2008: The treatment of neurospastic vascular diseases in Raynaud phenomenon Klinichna Khirurhiia 6: 36-39
Di Biase, A. 2013: Mesoglycan treatment in Raynaud phenomenon: a case series Minerva Cardioangiologica 61(3): 323-331
Adair, J.R.; Theobald, D.E. 1978: Raynaud's Phenomenon: treatment of a severe case with biofeedback Journal of the Indiana State Medical Association 71(10): 990-993
Kahan, A.; Weber, S.; Amor, B.; Guerin, F.; Degeorges, M. 1983: Nifedipine in the treatment of migraine in patients with Raynaud's phenomenon New England Journal of Medicine 308(18): 1102-1103
McKain, C.W.; Urban, B.J.; Goldner, J.L. 1983: The effects of intravenous regional guanethidine and reserpine. a controlled study Journal of Bone and Joint Surgery. American Volume 65(6): 808-811
Khalighi, M.R.; Haque, M.A.; Ziyai, K.; Firozian, F.; Parsaie, H. 1986: Influence of reserpine and guanethidine on the responses of the isolated rat ileum to catecholamines Indian Journal of Physiology and Pharmacology 30(2): 191-194
Dowd, P.M.; Martin, M.F.; Cooke, E.D.; Bowcock, S.A.; Jones, R.; Dieppe, P.A.; Kirby, J.D. 1982: Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2) British Journal of Dermatology 106(1): 81-89
Belch, J.J.; Shaw, B.; O'Dowd, A.; Saniabadi, A.; Leiberman, P.; Sturrock, R.D.; Forbes, C.D. 1985: Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study Thrombosis and Haemostasis 54(2): 490-494
Lakshminarayanan, S.; Vázquez-Abad, D.; Maestrello, S.J.; Waterman, J.R. 1999: Treatment of severe Raynaud's phenomenon and ischemic ulcerations with tissue plasimogen activator Clinical and Experimental Rheumatology 17(2): 260